GlaxoSmithKline unveils best results since merger
The news came after the British pharmaceuticals giant unveiled its best annual performance since 2000 when it was formed from the merger of SmithKline Beecham and Glaxo Wellcome. Strong sales of the asthma drug Advair propelled sales to £21.7bn last year, up 8 per cent. With pre-tax profits rising to £6.7bn, earnings per share were up 21 per cent to 82.6p, better than City expectations.
For this year, GSK's chief executive, Jean-Pierre Garnier, issued a cautious estimate of 10 per cent earnings growth, but said it could be higher if GSK gets "lucky" on generic challenges to some products. GSK will file Cervarix, its biggest new drug hope, to European regulators next month and it could be on the market next year. Pressure has increased on GSK to push on with getting the drug approved because Merck has submitted its experimental Gardasil shot in the US and Europe and just announced US regulators would give it a priority review. That means it could be launched in the US in June, six months before GSK even files for approval.
M. Garnier has always said there is a big potential market with room for two products. A company spokesman said yesterday there is a chance that US regulators could also speed up the approval process for Cervarix. Analysts have estimated Cervarix could bring in £2bn of sales a year, which would make it the biggest-selling vaccine ever.
Other exciting developments include Tykerb, a treatment for breast cancer, and Eltrombopag, a blood-clotting agent for use in cancer treatment. GSK expects eight major drugs to enter final phase III clinical trials this year.
M. Garnier reiterated the drugs pipeline was his main priority but added the company's strong balance sheet left it well placed to make strategic acquisitions. GSK has been eyeing the Swiss biotech Serono which it hopes to buy for a cut price after an auction for up to $15bn (£9bn) failed, according to insiders.
M. Garnier was tightlipped about Serono and Pfizer's consumer healthcare business, which might be sold or spun off. He also said GSK had sold its entire Relenza flu production for 2006 and parts of 2007. Governments are stockpiling the drug alongside Roche's Tamiflu in the event of a bird flu pandemic.
Diving in at the deep end is no excuse for shirking the style stakes
- 1 Why I'm on the brink of burning my Israeli passport
- 2 Japanese plant experts produce 10,000 lettuce heads a day in LED-lit indoor farm
- 3 War is war: Why I stand with Israel
- 4 L'Oreal cuts ties with Belgium supporter Axelle Despiegelaere after hunting trip photographs
- 5 The true Gaza back-story that the Israelis aren’t telling this week
Israel-Gaza conflict: Death toll tops 125 after overnight raids as Operation Protective Edge continues
Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
Ian Thorpe gay: Olympic swimmer comes out in Parkinson interview
Supermoon 2014: When and why will the moon look bigger and brighter this summer?
Gaza-Israel conflict: Pro-Palestinian demonstrators take to streets of London, Paris and New York in wave of protests
Sustained immigration has not harmed Britons' employment, say government advisers
War is war: Why I stand with Israel
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Australia facing international condemnation after turning around Sri Lankans at sea
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
iJobs Money & Business
£70000 per annum: Harrington Starr: Information Security Manager (ISO 27001, A...
£75000 - £85000 per annum + ex bens: Deerfoot IT Resources Limited: Biztalk Te...
£60000 per annum: Harrington Starr: Trade Desk Specialist (FIX, Linux, Windows...
£35000 per annum: Harrington Starr: Service Desk Analyst (Windows, Active Dire...